SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publications of positive preclinical data for TN-201, the company's gene therapy candidate for Myosin-Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM), in Nature Communications. Variants in the MYBPC3 gene resulting in insufficient levels of MyBP-C protein are the most common genetic cause of HCM. TN-201 is Tenaya's adeno-associated virus serotype 9 (AAV9)-based gene therapy

SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that new clinical and disease burden data pertaining to the company's MYBPC3-associated hypertrophic cardiomyopathy (HCM) program will be presented at the upcoming American College of Cardiology's Annual Scientific Session being held March 29-31, 2025 in Chicago, IL. Tenaya is advancing TN-201, an AAV9-based gene therapy for the potential treatment of MYBPC3-associated HCM, a condition caused by in

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker Presentation at the American College of Cardiology Meeting Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 Recent $48.9 Million Financing Extends Cash Runway into mid-2026 SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 75,000,000 total units for gross proceeds of approximately $52.5 million prior to deducting underwriting discounts and commissions and offering expenses.  Tenaya intends to use the net proceeds from the offering to fund the ongoing and planned development of its clinical and early-stage product candidates, particularly TN-201 and TN-401, and for work

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and Series A warrants and Series B warrants, each to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares of common stock at a purchase price of $0.001 per share, Series A warrants and Series B warrants. The pre-funded warrants

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in TD Cowen's 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Details are as follows: TD Cowen 45th Annual Health Care ConferenceDate: Tuesday, March 4Time: 1:10 PM ET – 1:40 PM ETFormat: Company Presentation Leerink Partners Global Healthcare Conference 2025Date: Wednesday, March 12Ti

Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Additional Cohort 1 Data to be Reported in 1H25 Building on Promising Initial Data Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies th

TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels Observed at One Year Circulating Biomarkers and Other Clinical Measures Mostly Remained Stable or Improved from Baseline Tenaya Management to Host a Webcast Conference Call Today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported encouraging

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17. Conference Call and Webcast Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register her

TN-401 AAV9-based Gene Therapy Designed to Deliver Fully Functional PKP2 Gene with the Aim of Increasing Protein Levels to Address Underlying Disease RIDGE-1 Currently Enrolling at Six Centers; Observational Natural History and Seroprevalence Study of PKP2-associated ARVC Adults Continues Enrollment at 20 Clinical Sites in the U.S., UK and Europe Initial Clinical Data for RIDGE-1 Anticipated in 2025 SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today annou

William Blair initiated coverage of Tenaya Therapeutics with a rating of Outperform

Leerink Partners initiated coverage of Tenaya Therapeutics with a rating of Outperform and set a new price target of $7.00

H.C. Wainwright initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $25.00

Cowen & Co. initiated coverage of Tenaya Therapeutics with a rating of Outperform

Morgan Stanley initiated coverage of Tenaya Therapeutics with a rating of Overweight and set a new price target of $31.00

Chardan Capital initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $37.00

Piper Sandler initiated coverage of Tenaya Therapeutics with a rating of Overweight and set a new price target of $40.00

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

3 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

S-3 - Tenaya Therapeutics, Inc. (0001858848) (Filer)

144 - Tenaya Therapeutics, Inc. (0001858848) (Subject)

10-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

SCHEDULE 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

SCHEDULE 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

SCHEDULE 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

424B5 - Tenaya Therapeutics, Inc. (0001858848) (Filer)

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within international commercial companies working across areas including strategy, finance, operations and governance. She is currently the Chief Financial and Business Officer a

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases. "We are pleased to welcome Ms. Burroughs to the Tenaya Board. Her substantial and diverse industry experience in the development and commercia

Company announces development candidate selection of its second gene therapy program, TN-401, targeting the leading genetic cause of arrhythmogenic right ventricular cardiomyopathy (gARVC) IND applications for TN-201 and TN-301 (previously named TYA-11631) expected to be submitted in the second half of 2022 Appoints Jennifer Drimmer, J.D., as General Counsel Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today provided a 2022 business update including the selection of TN-401 as the development candidate for the treatment of Genetic Arrhythmogenic

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced the appointments of Karah Parschauer, J.D., to its Board of Directors and of Joanna Auch as Senior Vice President of People and Culture. "Tenaya is at an important inflection point in our growth and maturity. We are now a public company with more than 100 employees who represent our commitment to internalize critical capabilities, including cGMP manufacturing and clinical development," said Faraz Ali, CEO of Tenaya. "Both Karah and Joanna are strong leaders who bring highly relevant strategic

TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels Observed at One Year Circulating Biomarkers and Other Clinical Measures Mostly Remained Stable or Improved from Baseline Tenaya Management to Host a Webcast Conference Call Today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported encouraging

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17. Conference Call and Webcast Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register her

SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

SC 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

SC 13G - Tenaya Therapeutics, Inc. (0001858848) (Subject)

SC 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)